Project Grant R24AI186591

Award Date 6/18/24
Completion Date 5/31/29
Dollars Obligated $1.2M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This Project Grant award from the John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $108,237 to Mbarara University of Science and Technology in Uganda to develop and assess the feasibility of a diagnostic tool for post-tuberculosis (TB) lung disease that can be deployed in primary healthcare settings. The key objectives are to: (1) create and validate a clinical diagnostic algorithm for post-TB lung disease, (2) conduct qualitative...
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to improve the detection and study of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) Develop new imaging technologies capable of detecting single MTB bacteria in vitro and in vivo; 2) Use...
This five-year, $813,838 project grant from the National Institute of Allergy and Infectious Diseases will fund research into the genetic and hormonal mechanisms underlying sex differences in tuberculosis (TB) and TB-HIV coinfection. The Johns Hopkins University will investigate how X chromosome complement and sex steroid hormones impact TB pathogenesis using cellular models, animal studies, and human samples. Researchers will utilize a novel four core genotype mouse model to differentiate the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the burden, severity, and phenotypic presentation of post-tuberculosis (TB) lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in TB patients with and without HIV. The total funding amount is $743,698.00 over the award period from Sep 20, 2024 to Aug 31, 2029. The grant will leverage an...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The award aims to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in TB control and reactivation, as well as characterize the cellular mechanisms of BMP pathway activation during TB...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to the University of California, Los Angeles (UCLA) to design and develop a rapid phenotypic drug susceptibility test, termed TRE-DST, for tuberculosis (TB). The TRE-DST system utilizes novel fluorescent trehalose probes to specifically detect live Mycobacterium tuberculosis (MTB) and determine drug...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $127,980.00 to The Johns Hopkins University for a five-year research project focused on integrating genomic and spatial data to develop more effective and efficient community-based tuberculosis (TB) screening and prevention interventions. The key objectives are to: 1) Refine estimates of subnational TB prevalence by...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,635,882 to The Johns Hopkins University to develop novel pro-apoptotic (cell death-inducing) host-directed therapies (HDTs) for shortening tuberculosis (TB) treatments and preventing post-TB lung damage. The research aims to leverage advanced imaging biomarkers and immunophenotyping to gain mechanistic insights on...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $265,650 to HMH Hospitals Corporation (Hackensack University Medical Center) to conduct research on novel rifabutin analogs as a strategy to overcome drug-resistant tuberculosis (MDR/RR-TB). The primary goals are to: (1) establish the structure-activity relationship and mechanism of action of MDR-TB active rifabutin...

A GLOBAL RESEARCH RESOURCE FOR HUMAN TUBERCULOSIS - ABSTRACT THERE IS A FUNDAMENTAL GAP IN OUR CURRENT UNDERSTANDING OF HOW MYCOBACTERIUM TUBERCULOSIS (MTB) CAUSES DISEASE IN THE HUMAN LUNG, AND SEVERAL REASONS ARE RESPONSIBLE FOR THIS LACK OF KNOWLEDGE. FIRSTLY, THE AVAILABILITY OF TUBERCULOUS HUMAN LUNG TISSUES PLUMMETED WITH THE INTRODUCTION OF ANTIBIOTICS IN THE 1940S AND 1950S. SECONDLY, TB RESEARCH USING ANIMALS RAPIDLY PROGRESSED AND NOVEL TECHNOLOGIES WERE APPLIED TO THESE MODEL SYSTEMS. HOWEVER, IT IS WELL KNOWN THAT NO ANIMAL MODEL REPRODUCES THE FULL SPECTRUM OF DISEASE AS IT OCCURS IN HUMANS, OR NATURALLY MEDIATES TRANSMISSION TO NEW HOSTS. NOT SURPRISINGLY, INTEREST IN HUMAN PULMONARY TB WAS REVIVED DECADES LATER WHEN IT WAS REALIZED THAT THE DISEASE HAD NEVER BEEN ERADICATED. DESPITE THIS, THERE ARE FEW STUDIES FOCUSED ON ELUCIDATING THE FUNDAMENTAL MECHANISMS OF ACTIVE, SUBCLINICAL, AND LATENT HUMAN TB, WHICH IS LIKELY DUE TO LIMITED ACCESS TO HUMAN TB LUNG TISSUE. WE BELIEVE THE TB FIELD CAN NO LONGER RELY ON ANIMAL MODELS THAT YIELD FINDINGS OF LIMITED CLINICAL RELEVANCE. THUS, THERE IS AN URGENT NEED TO BETTER UNDERSTAND HUMAN PULMONARY TB IN ORDER TO DEVELOP CLINICALLY RELEVANT THERAPEUTIC STRATEGIES. THE OVERALL GOAL OF THIS R24 PROPOSAL IS TO TRANSFORM THE GLOBAL LANDSCAPE OF TB RESEARCH BY ACCELERATING THE STUDY OF HUMAN TB TISSUE. WE WILL ACCOMPLISH THIS BY PROVIDING USER-REQUESTED SERVICES COMPRISED OF TWO COMPONENTS: (I) THE PATHOLOGICAL, CELLULAR, STRUCTURAL, AND/OR GENETIC ANALYSIS OF RESECTED HUMAN TB OR POSTMORTEM (PM) TISSUE AND (II), THE DISSEMINATION OF TISSUE TO THE GLOBAL TB RESEARCH COMMUNITY. WE HAVE SEVERAL UNIQUE ADVANTAGES SINCE AHRI, LOCATED IN DURBAN, SOUTH AFRICA, HAS ACCESS TO A CONTINUOUSLY GROWING COLLECTION OF ACTIVE TB/HIV AND PM SAMPLES, INCLUDING ENTIRE LUNGS/LOBES. THIS R24 PROPOSAL IS BUILT UPON SUBSTANTIAL PUBLISHED DATA FROM OUR GROUP THAT CLEARLY DEMONSTRATE OUR CAPACITY TO EXAMINE RESECTED AND PM LUNG TISSUE FROM MTB/HIV-INFECTED HUMAN SUBJECTS. THE RATIONALE FOR THIS PROPOSAL ARE (I) THAT BY PROVIDING THIS DEDICATED SERVICE TO THE TB RESEARCH COMMUNITY, NUMEROUS LABORATORIES WORLDWIDE WILL BE ABLE TO RAPIDLY ASCERTAIN THE CLINICAL RELEVANCE OF THEIR BASIC SCIENCE DISCOVERIES, WHICH WILL HELP REFINE THE FOCUS OF THEIR RESEARCH TO HAVE TRANSLATIONAL IMPACT, AND (II) OUR SERVICES WILL DRIVE THE DISCOVERY OF NEW HUMAN TB PARADIGMS, OR CHALLENGE EXISTING PARADIGMS, ULTIMATELY LEADING TO THE DEVELOPMENT OF CLINICALLY RELEVANT DIAGNOSTICS, ANTI-TB DRUGS, AND/OR VACCINES. THIS PROPOSAL IS SIGNIFICANT BECAUSE IT IS THE FIRST STEP IN A PROGRESSION OF INNOVATIVE SERVICES TO THE GLOBAL TB RESEARCH COMMUNITY THAT IS EXPECTED TO BOLSTER AND ACCELERATE TRANSLATIONAL AND CLINICAL RESEARCH TO EXPEDITE THE DISCOVERY OF INNOVATIVE NEW STRATEGIES TO IMPROVE DIAGNOSIS, PREVENTION, AND TREATMENT OF TB.

Posted 6/18/24, 12:00 AM